文献速递妇科

美国子宫内膜癌机器人手术应用:结局改善且费用未增加

Implementing robotic surgery for uterine cancer in the United States: Better outcomes without increased costs.
PubMed 文献 · Gynecol Oncol · 2019-11-25

该研究回顾性分析了2008年1月1日至2015年9月30日美国Premier医疗数据库35,224例子宫内膜癌全子宫切除术患者。结果显示机器人手术使用率从9.48%升至56.82%,开腹手术从70.4%降至28.1%,所有术式主要并发症、次要并发症及30天再入院率均下降,围术期30天总费用从11,048美元略降至10,322美元(P=0.08)。倾向性评分匹配后,机器人手术较开腹手术住院时间更短、30天并发症更少,费用相当。

要点

  • 研究期间机器人手术使用率从9.48%升至56.82%,开腹手术从70.4%降至28.1%。
  • 所有术式主要并发症降2.5%(P<.001)、次要并发症降2.9%(P=.001)、30天再入院降2.0%(P=.001)。
  • 匹配后机器人手术较开腹手术住院更短、30天并发症更少(20.1% vs 33.7%),费用相当。

核心结论

  • 机器人辅助手术促进了微创方式在全国子宫内膜癌中的广泛推广,降低了围术期并发症,且全国层面治疗相关30天总费用未增加。

研究设计与样本

  • 回顾性队列研究,数据来自美国Premier医疗数据库2008年1月1日至2015年9月30日成人子宫内膜癌全子宫切除术患者,共35,224例。

主要发现

  • 机器人手术使用率从9.48%升至56.82%,开腹手术从70.4%降至28.1%。
  • 所有术式主要并发症降低2.5%(P<.001)、次要并发症降低2.9%(P=.001)、30天再入院降低2.0%(P=.001)。
  • 围术期30天总费用从11,048美元降至10,322美元(P=.08)。
  • 倾向性评分1:1匹配后,机器人手术住院时间中位数2.0(2.0-3.0)天 vs 开腹手术4.0(3.0-6.0)天,vs 腹腔镜手术3.0(2.0-4.0)天(均P<.001)。
  • 匹配后机器人手术30天并发症20.1% vs 开腹手术33.7%(P<.001),围术期30天总费用中位数12,200(9,509-16,341)美元 vs 12,018(8,996-17,162)美元(P=.34)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the effect of robotic-assisted surgery implementation for treatment of endometrial cancer in the United States on 30-day clinical outcomes and costs. METHODS: We retrospectively reviewed data of adult patients who underwent total hysterectomy for endometrial cancer in the US hospitals in Premier Healthcare Database between January 1, 2008 and September 30, 2015. We conducted trend analyses comparing the proportions of surgical approaches with the associated clinical outcomes and costs over the study period using Mann-Kendall tests. Clinical outcomes and costs of robotic-assisted surgery, laparoscopic and open surgery have been compared after propensity score 1:1 matching in the most recent 3 years (January 1, 2013-September 30, 2015). RESULTS: Of a total of 35,224 patients, use of robotic-assisted surgery increased from 9.48% to 56.82% while open surgery decreased from 70.4% to 28.1% over the study period. A 2.5% decrease in major complications (P < .001), a 2.9% decrease in minor complications (P = .001), and a 2.0% decrease 30-day readmissions (P = .001) was observed across all surgical approaches. Perioperative 30-day total cost slightly decreased from US $11,048 to US $10,322 (P = .08). Among propensity-score matched patients, robotic-assisted surgery was associated with shorter hospitalization than open surgery (median [interquartile range], 2.0 [2.0-3.0] vs 4.0 [3.0-6.0] days) and laparoscopic surgery (2.0 [2.0-3.0] vs 3.0 [2.0-4.0] days), fewer 30-day complications (20.1% vs 33.7%) (all P < .001), and comparable perioperative 30-day total costs (median [interquartile range], US $12,200 [US $9,509-US $16,341] vs US $12,018 [US $8,996-US $17,162]; P = .34) with open surgery. CONCLUSION: Robotic-assisted surgery facilitated the widespread diffusion of a minimally invasive approach nationally for endometrial cancer, with reduction of perioperative morbidity and no increase in overall treatment-related 30-day costs at national level.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Casarin J, Song C, Multinu F, et al. Implementing robotic surgery for uterine cancer in the United States: Better outcomes without increased costs. Gynecol Oncol. 2019. PMID: 31780236. doi:10.1016/j.ygyno.2019.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。